| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000040978 |
| Receipt No. | R000046792 |
| Scientific Title | Study of changes in body composition by ingestion of test food |
| Date of disclosure of the study information | 2020/09/30 |
| Last modified on | 2021/01/05 (Ver. 4) |
| Basic information | ||
| Public title | Study of changes in body composition by ingestion of test food | |
| Acronym | Study of changes in body composition by ingestion of test food | |
| Scientific Title | Study of changes in body composition by ingestion of test food | |
| Scientific Title:Acronym | Study of changes in body composition by ingestion of test food | |
| Region |
|
|
| Condition | |||
| Condition | None | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Effects of food ingredients on body composition |
| Basic objectives2 | Others |
| Basic objectives -Others | Effects of food ingredients on muscle strength |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | body composition
muscle strength |
| Key secondary outcomes | questionnaire |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test food (4weeks). | |
| Interventions/Control_2 | Ingestion of placebo food (4weeks). | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Japanese individuals aged 20-50 years,who have recently lacked physical strength due to lack of exercise.
2) Individuals who can exercise regularly (at least 2-3 times a week) during the test period 3) Individuals who have not taken protein products intended to build muscle 4) Individuals who are healthy and are not suffered from a chronic malady. 5) Individuals whose written informed consent has been obtained. 6) Individuals who can visit an inspection facility and be inspected in designated days. 7) Individuals judged appropriate for the study by the principal. |
|||
| Key exclusion criteria | 1)Individuals using medical products.
2)Individuals who have a history of serious hepatopathy, kidney damage, heart disease, lung and blood disease. 3)Individuals who contract or have a history of serious gastrointestinal disease. 4)Individuals who have an addiction to alcohol or a mental illness. 5)Individuals who used or applied a drug for treatment of disease in the past 1 month. 6)Individuals with probable seasonal allergy, such as pollinosis, during the test period.(In particular, Betulaceae: alder, oba alnus firma, shirakaba, Taxodiaceae: cryptomeria, hinoki cypress, Asteraceae: ragweed, Artemisia vulgaris indica, Gramineae:Dactylis glomerata, Phleum pratense) 7)Individuals who have possibility of allergy symptoms onset by the test food and who cause severe allergic symptoms in foods and medicines. 8)Individuals cannnot drink milk or dairy products. 9)Individuals with serious anemia. 10)Individuals with high blood glucose(fasting blood glucose over 126mg/dL). 11)Individuals who are a smoker. 12)Females who are or are possibly pregnant, or are lactating. 13)Individuals whose life style will change during the test period. 14)Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period. 15)Individuals who were hospitalized and received treatment in the past 6 months. 16)Individuals who participated in other clinical studies in the past 1 months or will participate in other clinical studies during the test period. 17)Individuals judged inappropriate for the study by the principal. |
|||
| Target sample size | 40 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | MORINAGA & CO., LTD. | ||||||
| Division name | Health Science and Research Center, R&D institute | ||||||
| Zip code | 230-8504 | ||||||
| Address | 2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama | ||||||
| TEL | 045-571-6140 | ||||||
| h-uchida-ji@morinaga.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | MORINAGA & CO., LTD. | ||||||
| Division name | Health Science and Research Center, R&D institute | ||||||
| Zip code | 230-8504 | ||||||
| Address | 2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama | ||||||
| TEL | 045-571-6140 | ||||||
| Homepage URL | |||||||
| t-yamamoto-jc@morinaga.co.jp | |||||||
| Sponsor | |
| Institute | MORINAGA & CO., LTD. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | MORINAGA & CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Japan Conference of Clinical Research |
| Address | 1-13-23 Minamiikebukuro, Toshima-ku, Tokyo |
| Tel | 03-6868-7022 |
| None | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 40 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046792 |